{"id":69952,"date":"2026-07-14T15:04:55","date_gmt":"2026-07-14T07:04:55","guid":{"rendered":"https:\/\/flcube.com\/?p=69952"},"modified":"2026-07-14T15:04:56","modified_gmt":"2026-07-14T07:04:56","slug":"chinas-nhsa-completes-preliminary-review-of-2026-medical-insurance-catalog-with-91-pass-rate-for-basic-medicines","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69952","title":{"rendered":"China&#8217;s NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China&#8217;s <strong>National Healthcare Security Administration (NHSA)<\/strong> announced the completion of its <strong>preliminary formal review<\/strong> for the <strong>2026 medical insurance catalog adjustment<\/strong>, revealing that <strong>601 out of 664 generic drug names<\/strong> (91% pass rate) successfully advanced to the next stage of evaluation.<\/p>\n\n\n\n<h2 id=\"h-review-process-overview\" class=\"wp-block-heading\">Review Process Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Basic Medical Insurance Catalog<\/th><th>Commercial Insurance Innovative Drug Catalog<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Submissions<\/strong><\/td><td>800 submissions<\/td><td>62 submissions<\/td><\/tr><tr><td><strong>Generic Drug Names<\/strong><\/td><td>664<\/td><td>62<\/td><\/tr><tr><td><strong>Passed Formal Review<\/strong><\/td><td>601 (91% pass rate)<\/td><td>58 (94% pass rate)<\/td><\/tr><tr><td><strong>Outside Current Catalog<\/strong><\/td><td>368<\/td><td>57<\/td><\/tr><tr><td><strong>Within Current Catalog<\/strong><\/td><td>233<\/td><td>1<\/td><\/tr><tr><td><strong>Public Feedback Received<\/strong><\/td><td>103 pieces (combined)<\/td><td><\/td><\/tr><tr><td><strong>Drug Names Updated<\/strong><\/td><td>15 generic drug names<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications-for-pharmaceutical-industry\" class=\"wp-block-heading\">Strategic Implications for Pharmaceutical Industry<\/h2>\n\n\n\n<h3 id=\"h-high-pass-rates-signal-streamlined-process\" class=\"wp-block-heading\">High Pass Rates Signal Streamlined Process<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>91% basic catalog pass rate<\/strong> indicates NHSA has refined its formal review criteria, reducing administrative barriers for eligible products<\/li>\n\n\n\n<li><strong>94% commercial innovative drug catalog pass rate<\/strong> demonstrates strong government support for novel therapeutics in supplementary insurance coverage<\/li>\n\n\n\n<li><strong>Efficiency improvements<\/strong> likely reflect lessons learned from previous annual negotiations and catalog adjustments<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-market-access-opportunities\" class=\"wp-block-heading\">Market Access Opportunities<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>368 new drugs outside current catalog<\/strong> represent significant commercial opportunity for manufacturers seeking first-time reimbursement<\/li>\n\n\n\n<li><strong>233 existing catalog drugs<\/strong> undergoing re-evaluation may face price renegotiation or indication-specific coverage changes<\/li>\n\n\n\n<li><strong>Commercial insurance pathway<\/strong> provides alternative access route for innovative drugs that may not meet basic catalog cost-effectiveness thresholds<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-public-feedback-amp-quality-control\" class=\"wp-block-heading\">Public Feedback &amp; Quality Control<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>103 public comments<\/strong> received during feedback period demonstrate stakeholder engagement in transparent process<\/li>\n\n\n\n<li><strong>15 generic drug names updated<\/strong> following re-examination shows NHSA&#8217;s commitment to accuracy and responsiveness<\/li>\n\n\n\n<li><strong>Correction mechanism<\/strong> provides safety net for administrative errors while maintaining overall process integrity<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The NHSA&#8217;s annual catalog adjustment represents one of the world&#8217;s largest pharmaceutical pricing and reimbursement exercises, directly impacting market access for thousands of products serving China&#8217;s 1.4 billion population.<\/p>\n\n\n\n<h2 id=\"h-commercial-impact-amp-forward-outlook\" class=\"wp-block-heading\">Commercial Impact &amp; Forward Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Timeline Expectations:<\/strong> Final catalog decisions typically announced by year-end, with implementation effective January 1, 2027<\/li>\n\n\n\n<li><strong>Negotiation Phase:<\/strong> Drugs passing formal review now enter confidential price negotiations with NHSA<\/li>\n\n\n\n<li><strong>Market Dynamics:<\/strong> High pass rates may intensify competition among similar products, potentially driving steeper price concessions<\/li>\n\n\n\n<li><strong>Innovation Incentives:<\/strong> Dual-track approach (basic + commercial catalogs) creates tiered access system supporting both cost containment and innovation adoption<\/li>\n\n\n\n<li><strong>Industry Strategy:<\/strong> Manufacturers must prepare robust health economics data and flexible pricing strategies for upcoming negotiations<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding NHSA catalog inclusion, pricing negotiations, and market access outcomes. Actual results may differ due to risks including final regulatory decisions, competitive dynamics, and evolving healthcare policy priorities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s National Healthcare Security Administration (NHSA) announced the completion of its preliminary formal review for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[4],"tags":[67],"class_list":["post-69952","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-nhsa-prev-smia"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China&#039;s NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s National Healthcare Security Administration (NHSA) announced the completion of its preliminary formal review for the 2026 medical insurance catalog adjustment, revealing that 601 out of 664 generic drug names (91% pass rate) successfully advanced to the next stage of evaluation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69952\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China&#039;s NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines\" \/>\n<meta property=\"og:description\" content=\"China&#039;s National Healthcare Security Administration (NHSA) announced the completion of its preliminary formal review for the 2026 medical insurance catalog adjustment, revealing that 601 out of 664 generic drug names (91% pass rate) successfully advanced to the next stage of evaluation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69952\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-14T07:04:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-14T07:04:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69952#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69952\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China&#8217;s NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines\",\"datePublished\":\"2026-07-14T07:04:55+00:00\",\"dateModified\":\"2026-07-14T07:04:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69952\"},\"wordCount\":402,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"NHSA (prev. SMIA)\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69952#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69952\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69952\",\"name\":\"China's NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-14T07:04:55+00:00\",\"dateModified\":\"2026-07-14T07:04:56+00:00\",\"description\":\"China's National Healthcare Security Administration (NHSA) announced the completion of its preliminary formal review for the 2026 medical insurance catalog adjustment, revealing that 601 out of 664 generic drug names (91% pass rate) successfully advanced to the next stage of evaluation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69952#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69952\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69952#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China&#8217;s NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines - Insight, China&#039;s Pharmaceutical Industry","description":"China's National Healthcare Security Administration (NHSA) announced the completion of its preliminary formal review for the 2026 medical insurance catalog adjustment, revealing that 601 out of 664 generic drug names (91% pass rate) successfully advanced to the next stage of evaluation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69952","og_locale":"en_US","og_type":"article","og_title":"China's NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines","og_description":"China's National Healthcare Security Administration (NHSA) announced the completion of its preliminary formal review for the 2026 medical insurance catalog adjustment, revealing that 601 out of 664 generic drug names (91% pass rate) successfully advanced to the next stage of evaluation.","og_url":"https:\/\/flcube.com\/?p=69952","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-14T07:04:55+00:00","article_modified_time":"2026-07-14T07:04:56+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69952#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69952"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China&#8217;s NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines","datePublished":"2026-07-14T07:04:55+00:00","dateModified":"2026-07-14T07:04:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69952"},"wordCount":402,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["NHSA (prev. SMIA)"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69952#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69952","url":"https:\/\/flcube.com\/?p=69952","name":"China's NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-14T07:04:55+00:00","dateModified":"2026-07-14T07:04:56+00:00","description":"China's National Healthcare Security Administration (NHSA) announced the completion of its preliminary formal review for the 2026 medical insurance catalog adjustment, revealing that 601 out of 664 generic drug names (91% pass rate) successfully advanced to the next stage of evaluation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69952#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69952"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69952#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China&#8217;s NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69952"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69952\/revisions"}],"predecessor-version":[{"id":69953,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69952\/revisions\/69953"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}